ArticleNature communications2024
A structure-based designed small molecule depletes hRpn13
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Structures of dynamic interactors at native proteasomes by PhIX-MS and cryo-electron microscopy.Molecular cell · 2026Article
- Proteasome activity maintains cell-type-specific gene expression.Cell reports · 2026Article
- SCaN: A Screening and Characterization Platform for Nanosuspensions Enables In Vivo Delivery of a Crystalline hRpn13ACS pharmacology & translational science · 2026Article
- NMR in the Age of Modern Biomedical Research and Drug Discovery.Journal of molecular biology · 2025Review
- NMR-Guided Studies to Establish the Binding Interaction between a Peptoid and Protein.Journal of the American Chemical Society · 2025Article
- An adaptive peptide-binding site in ubiquitin receptor hRpn13 revealed by structural studies.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 1 country.
Xiuxiu LuProtein Processing Section, Center for Structural Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.ORCID 0000-0002-9591-7334
Monika ChandravanshiProtein Processing Section, Center for Structural Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Venkata R SabbasaniChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-4558-2812
Snehal GaikwadLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD, USA.
V Keith HughittLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Nana Gyabaah-KessieLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Bradley T ScrogginsRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sudipto DasProtein Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Wazo MyintCancer Innovation Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-2055-5180
Michelle E ClappGenome Modification Core, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Charles D SchwietersComputational Biomolecular Magnetic Resonance Core, Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Marzena A DybaBiophysics Resource, Center for Structural Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Derek L BolhuisDepartment of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Janusz W KoscielniakBasic Science Program, Leidos Biomedical Research Inc., NMR Facility for Biological Research, Center for Structural Biology, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Thorkell AndressonProtein Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
Michael J EmanueleDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-4104-7449
Nicholas G BrownDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-6141-0164
Hiroshi MatsuoCancer Innovation Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-4559-6157
Raj ChariGenome Modification Core, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-2216-313X
Deborah E CitrinRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Beverly A MockLaboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0003-2479-4549
Rolf E SwensonChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Kylie J WaltersProtein Processing Section, Center for Structural Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA. kylie.walters@nih.gov.ORCID 0000-0001-7590-2891
National Institutes of Health · USFrederick National Laboratory for Cancer Research · USNational Cancer Institute · USLeidos (United States) · USUniversity of North Carolina at Chapel Hill · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6MImaging Probe Development CenterZICHL005090 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI SWENSON, ROLF · 2011 to 2025
$22.2MUbiquitin signaling for protein degradationZIABC011490 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WALTERS, KYLIE · 2013 to 2025
$21.1MPreclinical Testing of HDAC, mTOR and MYC InhibitorsZIABC011065 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MOCK, BEVERLY · 2009 to 2025
$10.6MMOLECULAR AND CELLULAR BIOPHYSICS TRAINING PROGRAMT32GM008570 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KUHLMAN, BRIAN A, SLEP, KEVIN C · 1995 to 2022
$5.1MStructural studies of biomolecules related to cancer and HIV-AIDSZICBC011849 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MATSUO, HIROSHI · 2018 to 2024
$5.0MSpindle Assembly Checkpoint SilencingR35GM128855 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nicholas Gene Brown · 2018 to 2026
$4.1MStructurally dissecting APOBEC3's for HIV-1 restriction and beyondR01AI150478 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SCHIFFER, CELIA A. · 2019 to 2024
$3.9MSCF Ubiquitin Ligases in Cell Cycle Control and Chromosome StabilityR01GM120309 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EMANUELE, MICHAEL JAMES · 2016 to 2023
$2.3MProteostasis signaling in cell cycle controlR35GM153250 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael James Emanuele · 2024 to 2026
$1.9MStructurally dissecting APOBEC3's for HIV-1 restrictionR01GM118474 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SCHIFFER, CELIA A. · 2016 to 2018
$1.8MDeubiquitinases in Cell Cycle ControlR01GM134231 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EMANUELE, MICHAEL JAMES · 2020 to 2023
$1.6MIntramural NIH HHS ZIA BC011490NCI NIH HHS 75N91019D00024NIAID NIH HHS R01 AI150478NIGMS NIH HHS R01 GM118474NIGMS NIH HHS R01 GM120309NIGMS NIH HHS R01 GM134231NIGMS NIH HHS R35 GM128855NIGMS NIH HHS R35 GM153250NIGMS NIH HHS T32 GM008570
Abstract
Proteasome subunit hRpn13 is partially proteolyzed in certain cancer cell types to generate hRpn13
Indexed as
Membrane GlycoproteinsProteasome Endopeptidase ComplexCytoplasmIntracellular Signaling Peptides and ProteinsTranscription FactorsUbiquitinIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsProteasome Endopeptidase ComplexTranscription FactorsUbiquitin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.